Selumetinib for NF2-Related Schwannomatosis
brief summary
The goal of this clinical trial is to evaluate the efficacy and safety of the MEK1/2 inhibitor selumetinib in treating patients with neurofibromatosis type 2-related schwannomatosis (NF2-SWN), including both adults and children with inoperable or progressive tumors.
detailed description
NF2-related schwannomatosis (NF2-SWN) is a rare, autosomal dominant tumor predisposition syndrome characterized by bilateral vestibular schwannomas and multifocal schwannomas arising from cranial, spinal, and peripheral nerves, frequently leading to progressive hearing loss, neurological deficits, and substantial morbidity. This study will serve as a Substudy component of the "Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)" initiative, conducting a single-center, single-arm Phase II clinical trial aimed at evaluating the efficacy and safety of selumetinib in treating NF2-SWN-associated tumors. The study will enroll 20 patients diagnosed with NF2-related schwannomatosis (NF2-SWN) who have at least one measurable and progressive vestibular schwannoma and are aged ≥3 years. The primary endpoints include: ① Imaging response rate for NF2-SWN-associated vestibular schwannomas, assessed by a reduction of ≥20% in volume according to the REiNs criteria; ② Hearing response rate, defined as an improvement in speech recognition rate exceeding the 95% threshold difference. Secondary endpoints involve quality-of-life assessment: all patients will undergo evaluation using the NF2-SWN-specific Quality of Life Scale (NFTI-QOL), with additional pain scoring using the Numerical Rating Scale-11 (NRS-11) for patients with NF2-SWN-related intraspinal space-occupying lesions. The exploratory endpoints included: ① Imaging response rates for other NF2-SWN-related tumors excluding NF2-SWN-associated vestibular schwannomas: for meningiomas (non-vestibular schwannomas), objective imaging response defined as a volume reduction ≥20% per the REiNs criteria; for ependymomas, objective imaging response defined as a maximum diameter reduction ≥30% per the RECIST 1.1 criteria; total tumor burden; and the TSPO-PET/MRI-defined immune phenotype (immune-enriched vs. immune-depleted) and its association with treatment response in NF2-SWN-associated vestibular schwannomas. This study will provide further clinical evidence for targeted therapy of NF2-SWN.
official title
A Single-Center, Single-Arm, Phase II Study to Explore the Efficacy and Safety of MEK1/2 Inhibitor (MEKi) Selumetinib in the Treatment of Patients With NF2-Related Schwannomatosis